Skip to main content
. 2022 Apr 19;6(8):2536–2547. doi: 10.1182/bloodadvances.2021006280

Figure 1.

Figure 1.

Sample selection for the CORAL follow-up FAS and ITT populations. *All patients in CORAL follow-up were assumed to have histologically confirmed DLBCL or transformed lymphoma based on the CORAL studies.9,21 †CORAL patients were randomly assigned to receive rituximab-based 2L treatment, although 3 patients did not ultimately receive rituximab in 2L and were excluded in this step. ‡A large proportion of patients in CORAL follow-up did not have an Eastern Cooperative Oncology Group (ECOG) or central nervous system (CNS) assessment; those with a missing/unknown ECOG status or CNS assessment were included in the analyses to preserve the sample size. §The ITT population had N = 205 in both the adjusted and unadjusted analyses.